Overview JAB-2485 Activity in Adult Patients With Advanced Solid Tumors Status: Not yet recruiting Trial end date: 2026-08-01 Target enrollment: Participant gender: Summary This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors. Phase: Phase 1/Phase 2 Details Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.